Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 7/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117314 | 0.86 | KCNH2 (0.39) | GAABRD4HTR7SYKNPC1 | |
| SCHEMBL5201716 | 0.84 | CD274 (0.52) | GAAALDH1A1 | |
| SCHEMBL13813556 | 0.84 | PTGS2 (0.53) | GAABRD4SYKNPC1ALDH1A1 | |
| SCHEMBL4109868 | 0.82 | FYN (0.50) | GAABRD4SYKNPC1ALDH1A1 | |
| SCHEMBL4120272 | 0.82 | GAA (0.46) | GAABRD4SYKNPC1ALDH1A1 | |
| SCHEMBL4122811 | 0.82 | LOXL2 (0.53) | GAABRD4SYKNPC1ALDH1A1 | |
| SCHEMBL5202347 | 0.82 | GAA (0.47) | GAABRD4 | |
| SCHEMBL6191706 | 0.78 | GAA (0.41) | GAABRD4NPC1ALDH1A1MAPT | |
| SCHEMBL5679827 | 0.78 | TUBB1 (0.45) | GAABRD4SYKNPC1ALDH1A1 | |
| SCHEMBL4763764 | 0.78 | TGFBR1 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20060040986-A1 | Erythropoietin production accelerator | KOWA CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568691-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | Kowa Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176764-A1 | Medicine for treating cancer | KOWA CO., LTD (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6867221-B2 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1494670-A1 | MEDICINE FOR TREATING CANCER | Kowa Co., Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-1422219-A1 | CYCLIC AMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| WO-2003086397-A1 | MEDICINE FOR TREATING CANCER | KOWA CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
| US-6605620-B1 | Such as 4-(N-(4-Methoxyphenyl)-N-(3-(3,4,5-trimethoxy-phenyl)-benzoylamino)-1-((2 -(3,4,5-trimethoxyphenyl)pyridin-4-yl)-methyl)piperidine; treatment and prevention of cell adhesion or infiltration | KOWA CO., LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| US-6498169-B1 | CELL ADHESION AND INFILTRATION INHIBITORS; ANTIASTHMATICS, ANTIALLERGENS, ANTIRHEUMATICS, ANTIARTERIOSCLEROTICS, ANTIINFLAMMATORIES AND ANTI SJOGREN'S SYNDROME AGENTS | KOWA CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176764-A1 | Medicine for treating cancer | HDAC4, HDAC3, NR4A3 | GAA 3681/4885BRD4 27/4885HTR7 1490/4885 |
| US-20060040986-A1 | Erythropoietin production accelerator | EPOR, GHRHR, ARL1 | GAA 3222/4885BRD4 1432/4885HTR7 3747/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | GAA 3222/4885BRD4 1432/4885HTR7 3747/4885 |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | HRH3, HRH4, CNKSR1 | GAA 4050/4885BRD4 1020/4885HTR7 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.